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Abstract
Background: Major adverse cardiovascular events (MACE) constitutes the main cause of morbidity 
and mortality in ischemic heart failure (HF) patients. The prognostic value of the autonomic nervous 
system parameters and microvolt T-wave alternans (MTWA) in this issue has not been identified to 
date. The aim herein, was to assess the usefulness of the abovementioned parameters in the prediction 
of MACE in HF patients with left ventricular systolic dysfunction of ischemic origin.
Methods: Baroreflex sensitivity (BRS), heart rate variability (HRV), MTWA and other well-known 
clinical parameters were analyzed in 188 ischemic HF outpatients with left ventricular ejection fraction 
(LVEF) ≤ 50%. During 34 (14–71) months of follow-up, 56 (30%) endpoints were noted.
Results: Univariate Cox analyses revealed BRS (but not HRV), MTWA, age, New York Heart As-
sociation functional class III, LVEF, implantable cardioverter-defibrillator presence, use of diuretics 
and antiarrhythmic drugs, diabetes, and kidney insufficiency were defined as significant predictors of 
MACE. Pre-specified cut-off values for MACE occurrence for the aforementioned continuous parameters 
(age, LVEF, and BRS) were: ≥ 72 years, ≤ 33%, and ≤ 3 ms/mmHg, respectively. In a multivariate Cox 
analysis only BRS (HR 2.97, 95% CI 1.35–6.36, p < 0.006), and LVEF (HR 1.98, 95% CI 0.61–4.52, 
p < 0.038) maintained statistical significance in the prediction of MACE. 
Conclusions: Baroreflex sensitivity and LVEF are independent of other well-known clinical param-
eters in the prediction of MACE in patients with HF of ischemic origin and LVEF up to 50%. BRS  
≤ 3 ms/mmHg and LVEF ≤ 33% identified individuals with the highest probability of MACE during 
the follow-up period. (Cardiol J)
Key words: autonomic nervous system, baroreflex sensitivity, heart rate variability,  
microvolt T-wave alternans, heart failure, left ventricular dysfunction, ischemic  
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Introduction
Major adverse cardiovascular events (MACE) 
constitutes the main cause of morbidity and mortal-
ity in heart failure (HF) patients, particularly when 
ischemic etiology is involved [1]. The role and 
prognostic value of the autonomic nervous system 
(ANS) indices: baroreflex sensitivity (BRS) and 
heart rate variability (HRV), as well as microvolt 
T-wave alternans (MTWA), have been thoroughly 
confirmed in patients with HF concerning cardio-
vascular death (CVD) [2–8]. A robust body of the 
previous data focused on patients with HF and 
reduced ejection fraction, which have the most 
clinical evidence with regard to therapies, and 
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[9, 10]. However, the latest recommendations for 
the management of acute and chronic HF have 
defined a new category — HF with mid-range ejec-
tion fraction (HFmrEF), i.e. with left ventricular 
ejection fraction (LVEF) in the range of 40–49%. 
Research on HFmrEF has recently begun to ap-
pear, although, data remain scarce and the man-
agement is not clearly defined. Estimates show 
that HFmrEF is responsible for 13% to 24% of all 
HF cases [11], so from a practical point of view, it 
seems important to include this group of patients 
in clinical studies.
The role and prognostic value of ANS indices 
and MTWA in prediction MACE (which beside 
CVD involves non-fatal myocardial infarction [MI] 
and non-fatal stroke), especially in patients with 
LVEF up to 50%, requires further investigations. 
In this study, the authors aimed to examine this 
issue in HF patients with left ventricular systolic 
dysfunction of ischemic origin. 
Methods
The protocol of the study was approved by the 
Local Ethics Committee at the Medical University 
of Gdansk, and written informed consent was ob-
tained from all participants.
Patient’s selection
Between 2009 and 2018, 188 consecutive 
patients with stable ischemic HF (documented by 
prior MI, percutaneous coronary intervention, or 
coronary artery by-pass grafting) and LVEF ≤ 50% 
who visited the outpatient clinic, were enrolled in 
this single-center study. The protocol of the initial 
visit included anamnesis with particular emphasis 
on pharmacological treatment and comorbidities; 
information on the demographic status of the 
patients; physical examination; two-dimensional-
-transthoracic echocardiographic study; laboratory 
blood tests; ANS and MTWA assessment. Ad-
ditional inclusion criteria were as follows: sinus 
rhythm; a stable clinical condition for at least 
3 months before enrollment; optimal medical thera-
py for HF and complete coronary revascularization 
under current guidelines [9, 12–14]. The exclusion 
criteria were: age < 18 years; a history of prior 
sustained ventricular arrhythmia or cardiac arrest; 
permanent atrial fibrillation/flutter; ventricular 
paced rhythm due to atrioventricular block; New 
York Heart Association (NYHA) functional class IV, 
clinical features of coronary instability; a revas-
cularization (coronary angioplasty and/or surgery 
by-pass grafting) within 3 months before the study; 
incomplete coronary revascularization status 
(scheduled coronarography, coronary angioplasty 
or surgery by-pass graft); diabetes complicated by 
documented symptomatic peripheral neuropathy; 
inability to perform exercise test; poor general 
condition or non-cardiologic comorbidities with 
potential unfavorable effect on survival. 
Studied parameters
MTWA assessment. Detailed skin prepara-
tion including mild abrasion was performed to re-
duce the impedance between skin and the electrode 
and minimize the risk of artifacts. Next, special 
electrodes (High-Res high-resolution electrodes, 
Cambridge Heart — Spacelab’s Healthcare, Sno-
qualmie, WA, USA) were placed in three orthogonal 
Frank leads (X, Y, and Z). The exercise test was 
performed on a treadmill (Delmar Reynolds), in line 
with the protocol dedicated for MTWA testing i.e. 
with a gradual increment in heart rate, first to the 
range of 100–110 bpm and then to 110–120 bpm 
for at least 2 min. The data were analyzed with 
the CH2000 system utilizing a spectral method 
(Cambridge Heart, Inc., Bedford, MA, USA), and 
were finally verified by the physician performing 
the study. The detailed methodology was already 
precisely described in previous studies [2, 15, 16]. 
The results of the test were classified as nega-
tive (MTWA_neg), positive (MTWA_pos) or in-
determinate (MTWA_ind), and additionally, all 
non-negative results were classified jointly as 
MTWA_non-neg and were included for further 
analysis.
ANS assessment. Autonomic parameters 
were analyzed in a quiet room with dimmed lights 
between 08.00 am and 1.00 pm, all patients were 
asked to fast (at least 4 h) and to refrain from 
smoking and drinking coffee (at least 12 h) before 
the examination. After adjustment of measuring 
devices, and a 15 min stabilization period, resting 
electrocardiogram (ECG) (Mingograf 720C) and 
beat-to-beat non-invasive arterial blood pressure 
(Finapres 2300, Ohmeda) were continuously re-
corded for 10 min during spontaneous breathing. 
The collected data were transferred to a PC work-
station, processed with POLYAN software [17] 
and analyzed according to the described protocol 
[18, 19]. 
The information on RR interval (resolution 
1 ms) and systolic arterial pressure (SAP) were 
obtained automatically. BRS (ms/mmHg) was com-
puted by spectral analysis as the average value of 
the transfer function modulus (Blackman-Tukey 
method, 0.03 Hz-bandwidth Parzen window) be-
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tween SAP and RR interval time series in low 
frequency (LF, 0.04–0.15 Hz) band, independently 
from coherence values [18]. Then, based on col-
lected ECG data routine HRV frequency-domain 
indices such as LF (in ms2), high frequency (HF, 
0.14–0.4 Hz, in ms2), LF to HF ratio (LF/HF), and 
relative spectral powers in LF bands expressed in 
normalized units (LFnu) were analyzed. Further-
more, time-domain HRV parameters were calcu-
lated based on RR data, such as the standard de-
viation of normal-to-normal RR intervals (SDNN), 
the square root of the mean of squared differences 
between successive intervals (RMSSD), and per-
centage of adjacent RR intervals differing by more 
than 50 ms (pNN50). Also, the mean heart period 
(HP in ms) value was included in the analysis [20].
Follow-up
The routine assessment, which took place 
every 6 months (or earlier if clinically necessary) 
involved assessing the patient’s clinical condition 
and recorded study if any had occurred. A decision 
on potential implantation on an implantable cardio-
verter-defibrillator (ICD) as a primary prevention 
of sudden cardiac death (or CRT-D if needed) was 
at the discretion of the physician in charge. The 
endpoint of the study was 3-point MACE, defined 
as non-fatal MI, non-fatal stroke and CVD [21, 
22]. Non-fatal MI was recognized according to the 
Fourth Universal Definition of Myocardial Infarc-
tion Guidelines [23]. Non-fatal stroke was defined 
according to the World Health Organization (WHO) 
definition as rapidly developing clinical signs of 
focal (or global) disturbance of cerebral function 
lasting 24 h (unless interrupted by surgery) with no 
apparent causes other than of vascular origin [24]. 
CVD included: fatal stroke or MI; death attributed 
to HF; any sudden death including unobserved and 
unexpected death; fatal pulmonary or systemic 
embolism; death following a vascular operation, 
vascular procedure, or amputation. All deaths were 
confirmed against the patient’s death certificate 
information or medical documentation.
Statistical analysis
Database construction and statistical analysis 
were performed with STATISTICA 12 software 
(StatSoft, Poland) and R 2.15.2 environment. 
Continuous data were presented as the median 
(25th–75th percentiles), categorical as a number and 
percentage. Differences between the MACE(+) 
and MACE(–) groups were calculated with the 
Mann-Whitney U-test and for qualitative data 
with the c2 or Yates c2 test. The accuracy of pre-
specified cut-off values for analyzed parameters 
was determined by area (AUC) under the receiver-
operating characteristic (ROC) curve. An asso-
ciation between the analyzed parameters and the 
endpoint was assessed using the Cox univariate 
and multivariate proportional hazard models. The 
probabilities of reaching the primary endpoint 
over time, for pre-specified cut-off values for 
BRS and LVEF, were estimated using the Kaplan-
Meier method and compared with the log-rank test. 
A p value of less than 0.05 was considered statisti-
cally significant. 
Results
Clinical characteristics of the studied patients
Demographic, clinical and echocardiographic 
data, as well as parameters of the ANS and MTWA 
of the studied groups, are presented in Table 1. 
Briefly, the patients were approximately 64 (58–72) 
years old, most of them were males (92%), more 
than 90% underwent MI. During 34 (14–71) months 
of follow-up, 56 (30%) patients underwent MACE: 
7 had a non-fatal stroke, 5 non-fatal MI, and 44 
suffered from CVD. These patients were charac-
terized by worse echocardiographic parameters, 
i.e. lower LVEF and larger atrial size, fewer 
negative results in MTWA assessment, worse 
results derived from ANS testing such as lower 
BRS, LFnu, and LF/HF ratio values. Furthermore, 
antiarrhythmic and diuretic drugs were used more 
frequently in these patients, and more often they 
had diabetes and chronic kidney disease (in stage 
III or higher).
Predictors of the endpoint 
Univariate Cox analyses revealed age, NYHA 
III functional class, LVEF, ICD presence, use of 
diuretics and antiarrhythmic drugs, diabetes and 
glomerular filtration rate < 60 mL/min/1.73 m2 
as significant predictors of the MACE (Table 2). 
Only BRS and MTWA_non-neg, but not HRV 
indices (both time and frequency domain) proved 
to be statistically significant. Pre-specified cut-off 
values with a high predictive likelihood for MACE 
occurrence established by using area under ROC 
for the aforementioned continuous parameters 
(age, LVEF, and BRS) were: ≥ 72 years, ≤ 33%, and 
≤ 3 ms/mmHg, respectively (Table 3). In a multi-
variate Cox analysis, which included all parameters 
which proved to be statistically significant in the 
univariate test, only BRS and LVEF maintained 
statistical significance in the prediction of MACE 
(Table 2). Figures 1 and 2 presents the Kaplan-
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Table 1. Clinical, laboratory and echocardiographic characteristics of the study group and comparison 
between the major adverse cardiovascular events [MACE(+) and MACE(–)] groups.
All (n = 188) MACE(+) (n = 56) MACE(–) (n = 132) P*
Age [years] 64 (58–72) 65 (60–74) 64 (58–70) < 0.026
Male 173 (92%) 53 (95%) 120 (91%) 0.406
Myocardial infarction 171 (91%) 50 (89%) 121 (92%) 0.785
Revascularization 169 (90%) 53 (95%) 116 (88%) 0.195
ICD 113 (60%) 37 (66%) 76 (58%) 0.262
CRT-D 17 (9%) 5 (9%) 12 (9%) 1
NYHA class < 0.001
NYHA I 34 (18%) 3 (5%) 31 (23%)
NYHA II 122 (65%) 36 (64%) 86 (65%)
NYHA III 32 (17%) 17 (30%) 15 (11%)
Laboratory parameters
Hemoglobin [g/dL] 14 (13–15) 13.9 (13.0–14.5) 14.1 (13.3–14.8) 0.368
BNP [pg/mL] 108 (77–300) 238 (104–918) 104 (66–201) < 0.003
Echocardiographic parameters
LADs [mm] 45 (41–48) 46 (41–50) 44 (40–48) < 0.035
LVEF [%] 33 (27–40) 28 (23–32) 35 (30–42) < 0.001
MTWA results
MTWA_neg 59 (31%) 10 (18%) 49 (37%) < 0.021
MTWA_pos 84 (45%) 32 (57%) 52 (39%) < 0.021
MTWA_ind 45 (24%) 14 (25%) 31 (23%) < 0.021
MTWA_non-neg 129 (69%) 46 (82%) 83 (63%) < 0.010
ANS parameters
Mean HP [ms] 1031 (948–1136) 1021 (950–1109) 1033 (949–1148) 0.230
SDNN [ms] 25.3 (16.8–37.9) 20.2 (11.5–47.0) 25.5 (18.8–36.4) 0.229
RMSDD [ms] 17.1 (10.3–29.9) 19.7 (7.5–41.4) 16.9 (10.9–27.6) 0.470
pNN50 [%] 0.68 (0–7.9) 0.81 (0.0–10.5) 0.63 (0.0–6.9) 0.321
LFnu 51 (26.7–69.8) 31.3 (23.4–61.6) 54.1 (29.5–70.6) < 0.041
LF/HF 1 (0.38–2.31) 0.53 (0.3–1.6) 1.2 (0.4–2.40 < 0.041
BRS [ms/mmHg] 4.2 (2.2–6.7) 2.6 (1.9–4.9) 4.6 (2.3–7.8) < 0.001
Medications
Beta-adrenolytics 179 (95%) 52 (93%) 127 (96%) 0.286
ACEI or ARB 173 (92%) 52 (93%) 121 (92%) 1
Spironolactone/eplerenone 98 (52%) 30 (54%) 68 (51%) 0.874
Antiplatelet therapy 171 (91%) 51 (91%) 120 (91%) 1
Statins 169 (90%) 52 (93%) 117 (89%) 0.596
Digoxin 6 (3%) 3 (5%) 3 (2%) 0.359
Diuretics 86 (46%) 39 (70%) 50 (36%) < 0.001
Anti-arrhythmic 19 (10%) 11 (20%) 8 (6%) < 0.006
Concomitant diseases
Arterial hypertension 128 (68%) 35 (62%) 93 (70%) 0.313
Diabetes 51 (27%) 23 (41%) 28 (21%) < 0.012
GFR < 60 (mL/min/1.73 m2) 41 (22%) 23 (41%) 20 (14%) < 0.001
Hypercholesterolemia 128 (68%) 40 (71%) 92 (67%) 0.612
History of atrial fibrillation/flutter 39 (21%) 14 (25%) 25 (19%) 0.441
Smoking 139 (74%) 41 (73%) 98 (74%) 1
*p value for comparison between MACE(+) and MACE(–) groups; ACEI — angiotensin-converting enzyme inhibitor; ARB — angiotensin  
receptor blocker; BNP — B-type natriuretic peptide; BRS — baroreflex sensitivity; CRT-D — implantable cardioverter-defibrillator with cardiac 
resynchronization therapy; HP — heart period; LADs — left atrium diameter; LFnu — spectral power in low-frequency range expressed in  
normalized units; LF/HF — LF to high frequency ratio; LVEF — left ventricular ejection fraction; GFR — glomerular filtration rate; ICD —  
implantable cardioverter-defibrillator; MI — myocardial infarction; MTWA_ind — indeterminate result for microvolt T-wave alternans;  
MTWA_neg — negative result for microvolt T-wave alternans; MTWA_non-neg — positive and indeterminate results for microvolt T-wave 
alternans; MTWA_pos — positive result for microvolt T-wave alternans; NYHA — classification according to the New York Heart Association; 
pNN50 — proportion of successive R-R intervals that differ by more than 50 ms; QRS — QRS complex width; RMSSD — square root of the 
mean squared difference of successive R-R intervals; SDNN — standard deviation of the average R-R intervals of the sinus rhythm
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-Meier curves illustrating the probability of MACE 
depending on pre-specified cut-off values for LVEF 
and BRS during the follow-up period, while Figure 3 
illustrates the probability of endpoint for a com-
bined parameter (LVEF and BRS jointly). As it has 
been presented, both LVEF ≤ 33% and BRS ≤ 3 ms/ 
/mmHg assessed separately or jointly, can identify 
patients at highest risk of MACE occurrence.
Table 3. Prognostic accuracy of the pre-specified cut-off values for analyzed parameters as the  
predictors of major adverse cardiovascular events during the follow-up.
Parameters AUC (95% CI) Characteristics (95% CI) Predictive value (95% CI)
Sensitivity (%) Specificity (%) Positive (%) Negative (%)
Age ≥ 72 [years] 0.59 (0.5–0.68) 81 36 76 43
LVEF ≤ 33 [%] 0.79 (0.72–0.85) 69 79 89 51
BRS ≤ 3.0 [ms/mmHg] 0.65 (0.55–0.76) 69 64 85 41
AUC — area under the curve; BRS — baroreflex sensitivity; CI — confidence interval; LVEF — left ventricular ejection fraction
Table 2. Univariate and multivariate Cox models estimating the likelihood of major adverse  
cardiovascular events (MACE).
Parameter Unadjusted P* Adjusted P*
HR 95% CI HR 95% CI
Age ≥ 72 [years] 2.03 1.17–3.51 < 0.012 0.90 0.38–2.11 0.801
NYHA class III 2.02 1.14–3.59 < 0.016 1.35 0.57–3.20 0.327
LVEF ≤ 33 [%] 3.65 1.93–6.93 < 0.001 1.98 0.61–4.52 < 0.038
MTWA_non-neg 2.15 1.08–4.27 < 0.029 1.86 0.66–5.26 0.242
BRS ≤ 3.0 [ms/mmHg] 3.78 1.85–7.73 < 0.001 2.97 1.35–6.36 < 0.006
Diuretics 2.38 1.34–4.21 < 0.003 1.37 0.56–2.77 0.410
Diabetes 1.76 1.03–3.00 < 0.039 1.78 0.77–4.69 0.165
GFR < 60 (mL/min/1.73 m2) 2.33 1.37–3.99 < 0.002 1.13 0.49–2.57 0.778
*p value for comparison between MACE(+) and MACE(–) groups; BRS — baroreflex sensitivity CI — confidence interval; LVEF — left ventricular 
ejection fraction; GFR — glomerular filtration rate; HR — hazard ratio; MTWA_non-neg — positive and indeterminate results for microvolt  
T-wave alternans; NYHA — classification according to the New York Heart Association
Figure 1. Kaplan-Meier curves illustrating the probability of major adverse cardiovascular events (MACE) during the 
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Discussion
The observation that not only LVEF but also 
BRS can predict MACE in patients with ischemic 
left ventricular systolic dysfunction, even after 
adjusting for other clinical parameters (such as age, 
NYHA functional class, ICD presence, impaired 
renal function, diuretics and antiarrhythmic’s us-
ing, and diabetes), is the principal finding of the 
present study. The role of MTWA was proved only 
in univariate Cox analysis. According to available 
research, this is the first study analyses regarding 
the usefulness of ANS and MTWA parameters in 
the identification of high-risk individuals of MACE 
occurrence among patients with ischemic cardio-
myopathy and LVEF up to 50%. Previous investi-
gations concerning MACE risk assessment among 
patients with coronary artery disease were dedicat-
ed to other well-known clinical parameters [25, 26], 
which were also confirmed in the present study. 
The role of ANS indices and MTWA was previously 
proven for arrhythmic, cardiac and all-cause mortal-
ity [2–7, 19, 27–34], however not for MACE, which 
are common and relevant in this population [1]. 
Moreover, the vast majority of cited studies omit-
ted patients with ejection fraction 40–50%, who 
have similarly poor prognosis [35–39].
Prognostic value of MTWA indices  
in the identification of MACE
Univariate Cox analysis showed that non-
-negative MTWA is a prognostic risk factor for 
MACE occurrence, yet it was not confirmed in the 
multivariate analysis (Table 2). This could be due 
Figure 3. Kaplan-Meier curves illustrating the probability of major adverse cardiovascular events (MACE) during the 
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to the fact that abnormal MTWA, as a potential 
modulator of arrhythmic episodes, is mainly as-
sociated with the risk of these events [2, 31, 33, 
40–42]. Several studies have shown the usefulness 
of MTWA in predicting cardiac and overall mortal-
ity mainly in patients with reduced LVEF [6, 7, 34, 
43, 44]. However, in MACE, which is a complex 
endpoint, where the percentage of arrhythmias is 
relatively smaller, its prognostic value seems to 
be significantly lower. This was noted by Chow 
et al. [44], who stated that non-negative MTWA 
increases the risk of total and arrhythmic mortality 
but does not increase the risk of non-arrhythmic 
death. Another explanation may be the interpreta-
tion of indeterminate MTWA results. In patients 
with LVEF ≤ 35% indeterminate MTWA is associ-
ated with a poor prognosis — similar to the patients 
with positive MTWA [45]. Regarding the patients 
with higher LVEF, as it was shown in one of the 
largest meta-analyses, conducted by Merchant et 
al. [46], indeterminate MTWA results are not as-
sociated with such outcomes.
Prognostic value of ANS indices  
in the identification of MACE
In the present study, it was shown in both uni- 
and multivariate Cox analyses, the role of BRS in 
the prediction of MACE occurrence in patients with 
HF of ischemic origin and LVEF up to 50%. The 
pre-specified cut-off value for BRS (3 ms/mmHg) 
is consistent with the results acquired by other 
researchers, where BRS was determined by both 
invasive and non-invasive methods [3, 4, 19, 27, 
28, 47]. In the current study, patients with BRS 
below 3 ms/mmHg had a relative risk for MACE 
threefold higher than patients above the cut-off. 
Moreover, as Figure 3 presents, individuals with 
both LVEF £ 33% and BRS £ 3 ms/mmHg had 
the highest MACE probability over a 34-month 
follow-up period. In many previous studies, BRS 
was proved to have prognostic value in predicting 
various end-points, such as hospitalization due to 
HF exacerbation as well as arrhythmic, cardiovas-
cular, or all-cause mortality [3, 4, 8, 19, 27, 28, 47]. 
The results of our research show that BRS also has 
an important role in the prediction of MACE, which 
proves the fact that autonomic imbalance could 
have an enormous impact on the development of 
various cardiovascular complications, and that this 
parameter should be taken into account in risk 
stratification and clinical evaluation of HF patients.
Two recently published studies [48, 49], put in 
question earlier data from the literature regarding 
the role of autonomic tone parameters. However, 
the clinical characteristics of studied populations 
and duration of follow-up periods were different, 
therefore these results, as it was noticed in the com-
mentary by Parati et al. [50] should be interpreted 
with caution and should not be extrapolated to HF 
patients with other clinical characteristics [49].
Limitations of the study
The authors are well aware of the potential 
limitations of the study. Firstly, this was a fairly 
small, single-center study with strict inclusion cri-
teria, and thus needs confirmation in larger trials. 
Secondly, although the percentage of patients with 
HFmrEF is similar to that in the general popula-
tion of patients with HF, it should be noted that 
the group of patients with HFmrEF in this article 
was 50. Next, due to the nature of the methodology 
of ANS and MTWA evaluation, only patients with 
sinus rhythm were included in the study. Moreover, 
in this paper we primarily focused on the MACE 
assessment rather than assessing other important 
endpoints, e.g. hospitalization due to HF exacerba-
tion. Finally, during the follow-up period, ANS or 
MTWA evaluation was not repeated, which makes 
it difficult to assess the impact of potential changes 
occurring at that time.
Conclusions
Baroreflex sensitivity and LVEF are independ-
ent of other well-known clinical parameters (such 
as age, NYHA functional class, ICD presence, 
impaired renal function, diuretics and antiar-
rhythmic’s using, and diabetes), in the prediction 
of MACE in patients with left ventricular systolic 
dysfunction of ischemic origin and LVEF up to 50%. 
BRS ≤ 3 ms/mmHg and LVEF ≤ 33% identified 
individuals with the highest probability of MACE 
during the follow-up period.
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